Open Nav

Theracaine, LLC

  • Mark Schwartz, Theracaine

Generate investor interest, secondarily partnering interest

  • Date:Wednesday, October 17
  • Time:10:30 AM - 10:45 AM
  • Room:Olympic
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:The company is developing non-opioid, long acting pain medicines for post surgical indications which will provide the patient with long acting relief, the surgeon with pain relief solutions tailored to each surgery and patient, payers with affordable pain management solutions and investors with a low risk path to a large market
  • Company (under construction)
  • Company HQ City:Palo Alto
  • Company HQ Country:United States
  • Company HQ State:California                  
  • CEO/Top Company Official:Dr. Mark W. Schwartz
  • Main Therapeutic Focus:Pain Management
  • Lead Product in Development :THX 101 for non-opioid long acting control of post surgical pain
  • Development Phase of Primary Product:Pre-Clinical
  • Additional Information/Comments:The goal of the company is to provide: Patients with longer opioid-free pain relief for all common surgeries Surgeons with true 72 hours opioid-free solutions tailored to each surgical specialty, no foreign body left in the surgical site, easy to administer Payers with affordable state-of-the-art pain management solutions from one provider Investors a low risk capital efficient path to multi-billion dollar defensible global opportunity
  • Total Amount Raised to Date, In All Rounds:~$1M
Mark Schwartz